The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2021

Filed:

Feb. 15, 2017
Applicants:

Research Foundation of the City University of New York, New York, NY (US);

New York University School of Medicine, New York, NY (US);

Inventors:

Patricia A. Broderick, Bronx, NY (US);

Steven V. Pacia, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/1473 (2006.01); A61B 5/145 (2006.01); G01N 33/487 (2006.01); G01N 33/50 (2006.01); A61B 5/00 (2006.01); A61B 5/1468 (2006.01); C12Q 1/6883 (2018.01); A61B 34/20 (2016.01); A61B 5/0478 (2006.01);
U.S. Cl.
CPC ...
A61B 5/14735 (2013.01); A61B 5/0478 (2013.01); A61B 5/1468 (2013.01); A61B 5/1473 (2013.01); A61B 5/14507 (2013.01); A61B 5/14542 (2013.01); A61B 5/14546 (2013.01); A61B 5/4041 (2013.01); A61B 5/4082 (2013.01); A61B 5/4094 (2013.01); A61B 5/4845 (2013.01); A61B 34/20 (2016.02); C12Q 1/6883 (2013.01); G01N 33/48728 (2013.01); G01N 33/5058 (2013.01); G01N 33/5091 (2013.01); A61B 2562/0209 (2013.01); G01N 2800/2857 (2013.01); G01N 2800/302 (2013.01);
Abstract

The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not limited to, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention also provides methods of differentiating white matter from gray matter. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using sensors. The invention further provides methods of measuring the neurotoxicity of a material by comparing microvoltammograms of a neural tissue in the presence and absence of the material using the inventive sensors.


Find Patent Forward Citations

Loading…